Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1985 Sep;76(3):1182–1192. doi: 10.1172/JCI112074

Experimental pulmonary inflammatory injury in the monkey.

S D Revak 1, C L Rice 1, I U Schraufstätter 1, W A Halsey Jr 1, B P Bohl 1, R M Clancy 1, C G Cochrane 1
PMCID: PMC424019  PMID: 2995448

Abstract

Inflammatory pulmonary injury was induced in Macaca mulatta rhesus monkeys by the intrabronchial instillation of the formylated peptide norleu-leu-phe (FNLP) or phorbol myristate acetate (PMA). Indicators of pulmonary injury included an increase in mean protein content of bronchoalveolar lavage (BAL) fluid from 0.51 mg/ml in untreated animals to 3.74 mg/ml and 6.64 mg/ml in FNLP- and PMA-treated animals, respectively, the appearance of a diffuse pulmonary infiltrate in chest roentgenograms, and histologic evidence of a predominantly neutrophilic leukocytic infiltration. Concomitant with the appearance of pulmonary injury was the generation of proteases and oxidants in the BAL fluids. Neutrophil elastase, bound to alpha 1-protease inhibitor (alpha 1-PI), was found to increase from 0.47 micrograms/ml in untreated monkeys to 0.99 micrograms/ml in FNLP-treated animals and 1.23 micrograms/ml in monkeys receiving PMA. Radioiodinated human prekallikrein, instilled for 2 min into the inflammatory site and retrieved by lavaging, was found to have undergone proteolytic cleavage; this cleavage was not consistently inhibitable with the inclusion of antibody to elastase. BAL fluids were shown to contain an amidolytic activity when tested on the synthetic substrate H-D-pro-phe-arg-pNA. This activity was partially inhibitable with known inhibitors of active Hageman factor and kallikrein. beta-Glucuronidase levels in the BAL fluids increased from 0.85 U/ml to 4.36 U/ml and 8.25 U/ml in FNLP- and PMA-treated animals, respectively. Myeloperoxidase (MPO) levels also increased from 1.37 OD U/ml X min to 16.59 and 30.47 OD U/ml X min in the same groups of animals. Oxidant generation was also assessed in several different ways. The specific activity of the oxidant-sensitive inhibitor alpha 1-PI recovered in the BAL fluid decreased from 0.80 in control samples to 0.57 and 0.65 in FNLP- and PMA-treated animals. That this inactivation was due to oxidant injury of the molecule was confirmed by the return to full activity of four out of five BAL samples after their incubation with the reducing agent dithiothreitol in the presence of methionine sulfoxide peptide reductase. The specific activity of catalase in the BAL fluids of animals given 3-amino, 1,2,4 triazole (AT) 1 h before lavaging showed drops from 0.97 in untreated monkeys to 0.04 in FNLP-treated and 0.49 in PMA-treated monkeys. MPO levels also fell in the AT-treated injured animals from 16.59 to 0.85 delta OD/min X ml in FNLP animals in the absence and presence of AT, and 30.47 to 0.60 delta OD/min X ml in PMA-treated animals. Inhibition of MPO by AT was shown in vitro to be H2O2 dependent. Total glutathione levels in the BAL fluids did not change appreciably after FNLP or PMA treatment. These studies present substantial evidence of the generation of both proteases and oxidants during the establishment of acute pulmonary inflammatory injury in an experimental primate model.

Full text

PDF
1182

Images in this article

1184Image
on p.1184
1186Image
on p.1186
1186Image
on p.1186
1187Image
on p.1187

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. APPLEMAN D., HEIM W. G., PYFROM H. T. Effects of 3-amino-1, 2, 4-triazole (AT) on catalase and other compounds. Am J Physiol. 1956 Jul;186(1):19–23. doi: 10.1152/ajplegacy.1956.186.1.19. [DOI] [PubMed] [Google Scholar]
  2. Abrams W. R., Cohen A. B., Damiano V. V., Eliraz A., Kimbel P., Meranze D. R., Weinbaum G. A model of decreased functional alpha-1-proteinase inhibitor. Pulmonary pathology of dogs exposed to chloramine T. J Clin Invest. 1981 Nov;68(5):1132–1139. doi: 10.1172/JCI110357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Abrams W. R., Weinbaum G., Weissbach L., Weissbach H., Brot N. Enzymatic reduction of oxidized alpha-1-proteinase inhibitor restores biological activity. Proc Natl Acad Sci U S A. 1981 Dec;78(12):7483–7486. doi: 10.1073/pnas.78.12.7483. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Babior B. M., Kipnes R. S., Curnutte J. T. Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent. J Clin Invest. 1973 Mar;52(3):741–744. doi: 10.1172/JCI107236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bouma B. N., Miles L. A., Beretta G., Griffin J. H. Human plasma prekallikrein. Studies of its activation by activated factor XII and of its inactivation by diisopropyl phosphofluoridate. Biochemistry. 1980 Mar 18;19(6):1151–1160. doi: 10.1021/bi00547a018. [DOI] [PubMed] [Google Scholar]
  6. Brehe J. E., Burch H. B. Enzymatic assay for glutathione. Anal Biochem. 1976 Jul;74(1):189–197. doi: 10.1016/0003-2697(76)90323-7. [DOI] [PubMed] [Google Scholar]
  7. COHEN G., HOCHSTEIN P. Glucose-6-phosphate dehydrogenase and detoxification of hydrogen peroxide in human erythrocytes. Science. 1961 Dec 1;134(3492):1756–1757. doi: 10.1126/science.134.3492.1756. [DOI] [PubMed] [Google Scholar]
  8. Carp H., Janoff A. In vitro suppression of serum elastase-inhibitory capacity by reactive oxygen species generated by phagocytosing polymorphonuclear leukocytes. J Clin Invest. 1979 Apr;63(4):793–797. doi: 10.1172/JCI109364. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Carp H., Janoff A. Possible mechanisms of emphysema in smokers. In vitro suppression of serum elastase-inhibitory capacity by fresh cigarette smoke and its prevention by antioxidants. Am Rev Respir Dis. 1978 Sep;118(3):617–621. doi: 10.1164/arrd.1978.118.3.617. [DOI] [PubMed] [Google Scholar]
  10. Carp H., Miller F., Hoidal J. R., Janoff A. Potential mechanism of emphysema: alpha 1-proteinase inhibitor recovered from lungs of cigarette smokers contains oxidized methionine and has decreased elastase inhibitory capacity. Proc Natl Acad Sci U S A. 1982 Mar;79(6):2041–2045. doi: 10.1073/pnas.79.6.2041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Clancy R. M., Hugli T. E. The extraction of leukotrienes (LTC4, LTD4, and LTE4) from tissue fluids: the metabolism of these mediators during IgE-dependent hypersensitivity reactions in lung. Anal Biochem. 1983 Aug;133(1):30–39. doi: 10.1016/0003-2697(83)90218-x. [DOI] [PubMed] [Google Scholar]
  12. Cochrane C. G., Revak S. D. The participation of high molecular weight kininogen in hypotensive shock and intravascular coagulation. Clin Immunol Immunopathol. 1980 Mar;15(3):367–374. doi: 10.1016/0090-1229(80)90048-3. [DOI] [PubMed] [Google Scholar]
  13. Cochrane C. G., Spragg R., Revak S. D. Pathogenesis of the adult respiratory distress syndrome. Evidence of oxidant activity in bronchoalveolar lavage fluid. J Clin Invest. 1983 Mar;71(3):754–761. doi: 10.1172/JCI110823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Cohen A. B. The effects in vivo and in vitro of oxidative damage to purified alpha1-antitrypsin and to the enzyme-inhibiting activity of plasma. Am Rev Respir Dis. 1979 Jun;119(6):953–960. doi: 10.1164/arrd.1979.119.6.953. [DOI] [PubMed] [Google Scholar]
  15. Damiano V. V., Cohen A., Tsang A. L., Batra G., Petersen R. A morphologic study of the influx of neutrophils into dog lung alveoli after lavage with sterile saline. Am J Pathol. 1980 Aug;100(2):349–364. [PMC free article] [PubMed] [Google Scholar]
  16. Fligiel S. E., Ward P. A., Johnson K. J., Till G. O. Evidence for a role of hydroxyl radical in immune-complex-induced vasculitis. Am J Pathol. 1984 Jun;115(3):375–382. [PMC free article] [PubMed] [Google Scholar]
  17. Freer R. J., Day A. R., Radding J. A., Schiffmann E., Aswanikumar S., Showell H. J., Becker E. L. Further studies on the structural requirements for synthetic peptide chemoattractants. Biochemistry. 1980 May 27;19(11):2404–2410. doi: 10.1021/bi00552a019. [DOI] [PubMed] [Google Scholar]
  18. Friedland J., Silverstein E. A sensitive fluorimetric assay for serum angiotensin-converting enzyme. Am J Clin Pathol. 1976 Aug;66(2):416–424. doi: 10.1093/ajcp/66.2.416. [DOI] [PubMed] [Google Scholar]
  19. Goldstein I. M., Roos D., Kaplan H. B., Weissmann G. Complement and immunoglobulins stimulate superoxide production by human leukocytes independently of phagocytosis. J Clin Invest. 1975 Nov;56(5):1155–1163. doi: 10.1172/JCI108191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Hojima Y., Pierce J. V., Pisano J. J. Hageman factor fragment inhibitor in corn seeds: purification and characterization. Thromb Res. 1980 Oct 15;20(2):149–162. doi: 10.1016/0049-3848(80)90381-3. [DOI] [PubMed] [Google Scholar]
  21. Hyslop P. A., Sklar L. A. A quantitative fluorimetric assay for the determination of oxidant production by polymorphonuclear leukocytes: its use in the simultaneous fluorimetric assay of cellular activation processes. Anal Biochem. 1984 Aug 15;141(1):280–286. doi: 10.1016/0003-2697(84)90457-3. [DOI] [PubMed] [Google Scholar]
  22. Janoff A., Sloan B., Weinbaum G., Damiano V., Sandhaus R. A., Elias J., Kimbel P. Experimental emphysema induced with purified human neutrophil elastase: tissue localization of the instilled protease. Am Rev Respir Dis. 1977 Mar;115(3):461–478. doi: 10.1164/arrd.1977.115.3.461. [DOI] [PubMed] [Google Scholar]
  23. Johnson D., Travis J. Inactivation of human alpha 1-proteinase inhibitor by thiol proteinases. Biochem J. 1977 Jun 1;163(3):639–641. doi: 10.1042/bj1630639. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Johnson D., Travis J. Structural evidence for methionine at the reactive site of human alpha-1-proteinase inhibitor. J Biol Chem. 1978 Oct 25;253(20):7142–7144. [PubMed] [Google Scholar]
  25. Johnson D., Travis J. The oxidative inactivation of human alpha-1-proteinase inhibitor. Further evidence for methionine at the reactive center. J Biol Chem. 1979 May 25;254(10):4022–4026. [PubMed] [Google Scholar]
  26. Johnson K. J., Fantone J. C., 3rd, Kaplan J., Ward P. A. In vivo damage of rat lungs by oxygen metabolites. J Clin Invest. 1981 Apr;67(4):983–993. doi: 10.1172/JCI110149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Johnson K. J., Ward P. A. Acute and progressive lung injury after contact with phorbol myristate acetate. Am J Pathol. 1982 Apr;107(1):29–35. [PMC free article] [PubMed] [Google Scholar]
  28. Kaplan A. P., Austen K. F. A pre-albumin activator of prekallikrein. J Immunol. 1970 Oct;105(4):802–811. [PubMed] [Google Scholar]
  29. Kazmierowski J. A., Gallin J. I., Reynolds H. Y. Mechanism for the inflammatory response in primate lungs. Demonstration and partial characterization of an alveolar macrophage-derived chemotactic factor with preferential activity for polymorphonuclear leukocytes. J Clin Invest. 1977 Feb;59(2):273–281. doi: 10.1172/JCI108638. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Klebanoff S. J., Rosen H. Ethylene formation by polymorphonuclear leukocytes. Role of myeloperoxidase. J Exp Med. 1978 Aug 1;148(2):490–506. doi: 10.1084/jem.148.2.490. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  32. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  33. Lee C. T., Fein A. M., Lippmann M., Holtzman H., Kimbel P., Weinbaum G. Elastolytic activity in pulmonary lavage fluid from patients with adult respiratory-distress syndrome. N Engl J Med. 1981 Jan 22;304(4):192–196. doi: 10.1056/NEJM198101223040402. [DOI] [PubMed] [Google Scholar]
  34. MARGOLIASH E., NOVOGRODSKY A. A study of the inhibition of catalase by 3-amino-1:2:4:-triazole. Biochem J. 1958 Mar;68(3):468–475. doi: 10.1042/bj0680468. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. MARGOLIASH E., NOVOGRODSKY A., SCHEJTER A. Irreversible reaction of 3-amino-1:2:4-triazole and related inhibitors with the protein of catalase. Biochem J. 1960 Feb;74:339–348. doi: 10.1042/bj0740339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Mancini G., Carbonara A. O., Heremans J. F. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry. 1965 Sep;2(3):235–254. doi: 10.1016/0019-2791(65)90004-2. [DOI] [PubMed] [Google Scholar]
  37. Matheson N. R., Wong P. S., Travis J. Enzymatic inactivation of human alpha-1-proteinase inhibitor by neutrophil myeloperoxidase. Biochem Biophys Res Commun. 1979 May 28;88(2):402–409. doi: 10.1016/0006-291x(79)92062-x. [DOI] [PubMed] [Google Scholar]
  38. McConahey P. J., Dixon F. J. A method of trace iodination of proteins for immunologic studies. Int Arch Allergy Appl Immunol. 1966;29(2):185–189. doi: 10.1159/000229699. [DOI] [PubMed] [Google Scholar]
  39. McGuire W. W., Spragg R. G., Cohen A. B., Cochrane C. G. Studies on the pathogenesis of the adult respiratory distress syndrome. J Clin Invest. 1982 Mar;69(3):543–553. doi: 10.1172/JCI110480. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Meier H. L., Kaplan A. P., Lichtenstein L. M., Revak S., Cochrane C. G., Newball H. H. Anaphylactic release of a prekallikrein activator from human lung in vitro. J Clin Invest. 1983 Aug;72(2):574–581. doi: 10.1172/JCI111005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Merritt T. A., Cochrane C. G., Holcomb K., Bohl B., Hallman M., Strayer D., Edwards D. K., 3rd, Gluck L. Elastase and alpha 1-proteinase inhibitor activity in tracheal aspirates during respiratory distress syndrome. Role of inflammation in the pathogenesis of bronchopulmonary dysplasia. J Clin Invest. 1983 Aug;72(2):656–666. doi: 10.1172/JCI111015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. O'Brodovich H. M., Stalcup S. A., Pang L. M., Lipset J. S., Mellins R. B. Bradykinin production and increased pulmonary endothelial permeability during acute respiratory failure in unanesthetized sheep. J Clin Invest. 1981 Feb;67(2):514–522. doi: 10.1172/JCI110061. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  43. O'Flaherty J. T., Cousart S., Lineberger A. S., Bond E., Bass D. A., DeChatelet L. R., Leake E. S., McCall C. E. Phorbol myristate acetate: in vivo effects upon neutrophils, platelets, and lung. Am J Pathol. 1980 Oct;101(1):79–92. [PMC free article] [PubMed] [Google Scholar]
  44. O'Flaherty J. T., Showell H. J., Becker E. L., Ward P. A. Substances which aggregate neutrophils. Mechanism of action. Am J Pathol. 1978 Jul;92(1):155–166. [PMC free article] [PubMed] [Google Scholar]
  45. Pannell R., Johnson D., Travis J. Isolation and properties of human plasma alpha-1-proteinase inhibitor. Biochemistry. 1974 Dec 17;13(26):5439–5445. doi: 10.1021/bi00723a031. [DOI] [PubMed] [Google Scholar]
  46. Schraufstätter I. U., Revak S. D., Cochrane C. G. Proteases and oxidants in experimental pulmonary inflammatory injury. J Clin Invest. 1984 Apr;73(4):1175–1184. doi: 10.1172/JCI111303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Shasby D. M., Vanbenthuysen K. M., Tate R. M., Shasby S. S., McMurtry I., Repine J. E. Granulocytes mediate acute edematous lung injury in rabbits and in isolated rabbit lungs perfused with phorbol myristate acetate: role of oxygen radicals. Am Rev Respir Dis. 1982 Apr;125(4):443–447. doi: 10.1164/arrd.1982.125.4.443. [DOI] [PubMed] [Google Scholar]
  48. Shasby D. M., Vanbenthuysen K. M., Tate R. M., Shasby S. S., McMurtry I., Repine J. E. Granulocytes mediate acute edematous lung injury in rabbits and in isolated rabbit lungs perfused with phorbol myristate acetate: role of oxygen radicals. Am Rev Respir Dis. 1982 Apr;125(4):443–447. doi: 10.1164/arrd.1982.125.4.443. [DOI] [PubMed] [Google Scholar]
  49. Showell H. J., Freer R. J., Zigmond S. H., Schiffmann E., Aswanikumar S., Corcoran B., Becker E. L. The structure-activity relations of synthetic peptides as chemotactic factors and inducers of lysosomal secretion for neutrophils. J Exp Med. 1976 May 1;143(5):1154–1169. doi: 10.1084/jem.143.5.1154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Sinet P. M., Heikkila R. E., Cohen G. Hydrogen peroxide production by rat brain in vivo. J Neurochem. 1980 Jun;34(6):1421–1428. doi: 10.1111/j.1471-4159.1980.tb11222.x. [DOI] [PubMed] [Google Scholar]
  51. Stansell M. J., Deutsch H. F. Preparation of crystalline erythrocuprein and catalase from human erythrocytes. J Biol Chem. 1965 Nov;240(11):4299–4305. [PubMed] [Google Scholar]
  52. Till G. O., Johnson K. J., Kunkel R., Ward P. A. Intravascular activation of complement and acute lung injury. Dependency on neutrophils and toxic oxygen metabolites. J Clin Invest. 1982 May;69(5):1126–1135. doi: 10.1172/JCI110548. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Ward P. A., Till G. O., Kunkel R., Beauchamp C. Evidence for role of hydroxyl radical in complement and neutrophil-dependent tissue injury. J Clin Invest. 1983 Sep;72(3):789–801. doi: 10.1172/JCI111050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Weissmann G., Smolen J. E., Korchak H. M. Release of inflammatory mediators from stimulated neutrophils. N Engl J Med. 1980 Jul 3;303(1):27–34. doi: 10.1056/NEJM198007033030109. [DOI] [PubMed] [Google Scholar]
  55. Wuepper K. D., Cochrane C. G. Plasma prekallikrein: isolation, characterization, and mechanism of activation. J Exp Med. 1972 Jan;135(1):1–20. doi: 10.1084/jem.135.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Zaslow M. C., Clark R. A., Stone P. J., Calore J. D., Snider G. L., Franzblau C. Human neutrophil elastase does not bind to alpha 1-protease inhibitor that has been exposed to activated human neutrophils. Am Rev Respir Dis. 1983 Sep;128(3):434–439. doi: 10.1164/arrd.1983.128.3.434. [DOI] [PubMed] [Google Scholar]
  57. Zigmond S. H. Chemotaxis by polymorphonuclear leukocytes. J Cell Biol. 1978 May;77(2):269–287. doi: 10.1083/jcb.77.2.269. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES